ArticleFrontiers in endocrinology2025
Age trend and risk factors of height loss in Chinese over 40 years old.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimizing early triage for subclinical cardiovascular-kidney-metabolic syndrome: longitudinal associations, incremental value, and clinical utility of nine insulin resistance surrogates.Cardiovascular diabetology · 2026Article
- Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To evaluate age-related height loss trend in men and women in China, and analyze associated risk factors, we conducted a cross-sectional study among 1286 participants from the Bone Health Improvement Program. Methods: Laboratory data were derived from the medical system and clinical risk factors of osteoporosis and fracture were collected through questionnaires. BMD was measured by DXA. Height loss was calculated as the difference between currently measured height and the highest self-reported height. Results: The study cohort comprised 706 males and 580 females, aged between 40 and 80 years, categorized into four age groups. The average height loss among men aged 70-80 was 9.5 times greater than men aged 40-50, while for women it was found to be 7.2 higher. Both genders experienced accelerated height loss after age 60; furthermore, women lose their height faster than men across all age groups. Multivariate logistic regression analysis including clinical risk factors, the best predictors of male height loss ≥4 cm were age (OR = 1.182, 95% CI: 1.111-1.258), rheumatoid arthritis (OR = 0.857, 95% CI: 0.788-0.933) and type 2 diabetes (OR = 3.012, 95% CI: 1.193-7.604), while for women, it was age (OR = 1.278, 95% CI: 1.182-1.382) and height (OR = 0.802, 95% CI: 0.714-0.901). In the multivariate logistic regression analysis involving laboratory data, the best predictive factors for male height loss ≥4 cm were eosinophil ratio (OR = 1.448, 95% CI: 1.11-1.89), fasting plasma glucose (OR = 0.469, 95% CI: 0.287-0.768), glycated hemoglobin (OR = 5.65, 95% CI: 2.511-12.711), and serum sodium levels (OR = 1.328, 95% CI: 1.112-1.585), while females had platelets counts (OR = 0.994, 95%CI: 0.989-1.000), glycated hemoglobin (OR = 1.413, 95% CI: 1.090-1.832), blood urea nitrogen levels (OR = 1.416, 95% CI: 1.147-1.747) and serum globulin levels (OR = 1.092, 95% CI: 1.01-1.18). The ROC curve areas for the models were 92.6%, 87.3%, 79%, and 68.1%, respectively. Discussion: In Chinese aged over 40 years, the rate of height loss significantly accelerates after age 60, regardless of gender. The discovery of risk factors associated with height loss is beneficial for the early identification of individuals with height loss ≥4 cm, to facilitate the early detection of bone loss and enable further examination and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.